[Safety and immunogenecity of a vaccine of polyssacharide Vi from Salmonella typhi in Cuban youths].
A randomized, controlled and double-blind study was conducted in young adults aged 18-20 aimed at evaluating the reactogenecity and immunogenecity of vaz-TyVi, a vaccine of polyssacharide Vi from Salmonella typhi. They were distributed into 3 groups: immunized with a dose of Vax-TyVi (Finlay Institute), TYPHIM Vi (Pasteur-Mérieux) or vax-TET (tetanic toxoid). Serum samples were taken before and 21 days after immunization. The immunogenecity was evaluated in 323 volunteers by an indirect ELISA. The seroconversion of those receiving vax-TyVi was 81.97% and 65.05 % for TYPHIM Vi. The postvaccine mean geometric titers were 7.41 U/mL (5.92-9.27 U/mL) and 5.41 U/mL (4.35-6.72 U/mL), respectively. The seroconversion with vax-TET was 0%. The reactogenecity of both polysaccharide vaccines was low. It was concluded that the immunogenecity of vax-TyVi was not lower than that of TYPHIM Vi and that its reactogenecity was similar.
Azze
Rolando Felipe Ochoa
RF
Instituto "Carlos J. Finlay", Ciudad de La Habana, Cuba. ochoa@finlay.edu.cu
Suárez
Idalia Morelia Baró
IM
Rodríguez
Juan Carlos Martínez
JC
Sosa
Mayelin Mirabal
MM
del Río
Marlene Isabel Armesto
MI
Alvarez
Francisco Domínguez
FD
D000293:Adolescent; D000328:Adult; D003462:Cuba; D004311:Double-Blind Method; D006801:Humans; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D022562:Salmonella Vaccines / Q000276:immunology*
D011135:Polysaccharides, Bacterial; D022562:Salmonella Vaccines; C054154:capsular polysaccharide, Salmonella